[HTML][HTML] Relapsed rhabdomyosarcoma
CM Heske, L Mascarenhas - Journal of clinical medicine, 2021 - mdpi.com
Relapsed rhabdomyosarcoma (RMS) represents a significant therapeutic challenge. Nearly
one-third of patients diagnosed with localized RMS and over two-thirds of patients with …
one-third of patients diagnosed with localized RMS and over two-thirds of patients with …
Rhabdomyosarcoma: an overview
R Dagher, L Helman - The oncologist, 1999 - academic.oup.com
Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin thought to arise
from cells committed to a skeletal muscle lineage. With approximately 250 cases diagnosed …
from cells committed to a skeletal muscle lineage. With approximately 250 cases diagnosed …
Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma
NF Esnaola, BP Rubin, EH Baldini… - Annals of …, 2001 - journals.lww.com
Summary Background Data The literature on adult rhabdomyosarcoma is limited. Few
studies have identified predictors of long-term survival in this patient population. Methods …
studies have identified predictors of long-term survival in this patient population. Methods …
Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma
TM Dantonello, C Int-Veen, P Winkler… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Evaluation of primary tumor-, treatment-, and patient-related factors predicting
relapse pattern, risk, and survival after relapse with the aim to design a risk-adapted, tumor …
relapse pattern, risk, and survival after relapse with the aim to design a risk-adapted, tumor …
Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group
L Mascarenhas, ER Lyden, PP Breitfeld… - Cancer, 2019 - Wiley Online Library
Background The purpose of this study was to evaluate risk and response–based multi‐agent
therapy for patients with rhabdomyosarcoma (RMS) at first relapse. Methods Patients with …
therapy for patients with rhabdomyosarcoma (RMS) at first relapse. Methods Patients with …
Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups
O Oberlin, A Rey, E Lyden, G Bisogno… - Journal of Clinical …, 2008 - ascopubs.org
Purpose To identify risk factors associated with outcome in children with metastatic
rhabdomyosarcoma in a large cohort of patients Patients and Methods Pooled data were …
rhabdomyosarcoma in a large cohort of patients Patients and Methods Pooled data were …
Metastatic rhabdomyosarcoma: evidence of the impact of radiotherapy on survival. A retrospective single‐center experience
A Ferrari, L Bergamaschi, S Chiaravalli… - Pediatric Blood & …, 2022 - Wiley Online Library
Background The prognosis for patients with metastatic rhabdomyosarcoma (RMS) remains
largely unsatisfactory despite the adoption of intensive multimodal therapy. To assess the …
largely unsatisfactory despite the adoption of intensive multimodal therapy. To assess the …
Does surgery have a role in the treatment of local relapses of non‐metastatic rhabdomyosarcoma?
F De Corti, G Bisogno, P Dall'Igna… - Pediatric Blood & …, 2011 - Wiley Online Library
Purpose Patients with non‐metastatic rhabdomyosarcoma (RMS) have a cure rate of 50–
90%, but up to one‐third of them experience mostly a local recurrence. Second‐line …
90%, but up to one‐third of them experience mostly a local recurrence. Second‐line …
Adult rhabdomyosarcoma: outcome following multimodality treatment
DJ Little, MT Ballo, GK Zagars… - … Journal of the …, 2002 - Wiley Online Library
BACKGROUND Childhood rhabdomyosarcoma (RMS) has a relatively good prognosis.
Outcome for adults with this disease is poorly documented due to its rarity. METHODS The …
Outcome for adults with this disease is poorly documented due to its rarity. METHODS The …
Randomized phase II trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: a report from the Children's …
L Mascarenhas, YY Chi, P Hingorani… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus
for additional investigation in rhabdomyosarcoma (RMS) when administered in combination …
for additional investigation in rhabdomyosarcoma (RMS) when administered in combination …